NFE2L2 and chronic kidney disease: Accordingly, the bardoxolone derivative (RTA) DH404 activated NRF2 and conferred anti-inflammatory effects (via suppression of the transcription factor NF-κB) and normalized ROS formation and endothelial dysfunction in animals with chronic kidney disease or diabetes [56,57,58].